CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗中的精准重编程：先进基因编辑的创新、挑战与未来方向
英文原题：Precision Reprogramming in CAR-T Cell Therapy: Innovations, Challenges, and Future Directions of Advanced Gene Editing.
查看英文原题
Precision Reprogramming in CAR-T Cell Therapy: Innovations, Challenges, and Future Directions of Advanced Gene Editing.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）-T 细胞疗法代表了癌症免疫治疗的一项突破，尤其在血液系统恶性肿瘤中展现出令人瞩目的临床疗效。然而，其更广泛的治疗应用，特别是针对实体瘤，仍然受限。关键挑战包括 T 细胞耗竭、持续性有限、细胞因子介导的毒性，以及与自体产品生产相关的物流障碍。新兴的基因编辑技术，如 CRISPR/Cas 系统、碱基编辑和先导编辑，为优化 CAR-T 细胞提供了新途径，旨在增强疗效的同时控制毒性并提高可及性。本综述全面审视了这些基因编辑工具在 CAR-T 细胞治疗中的应用现状，重点介绍了最新进展、持续存在的挑战以及未来方向。借助基因编辑，有望将 CAR-T 疗法转变为一种更有效、更安全且适用范围更广的治疗手段，用于癌症及其他疾病。
展开英文摘要原文
Chimeric antigen receptor (CAR)-T cell therapy represents a breakthrough in cancer immunotherapy, demonstrating impressive clinical outcomes, particularly for hematologic malignancies.
However, its broader therapeutic application, especially against solid tumors, remains limited. Key challenges include T cell exhaustion, limited persistence, cytokine-mediated toxicities, and logistical hurdles associated with manufacturing autologous products. Emerging gene editing technologies, such as CRISPR/Cas systems, base editing, and prime editing, offer novel approaches to optimize CAR-T cells, aiming to enhance efficacy while managing toxicity and improving accessibility.
This review comprehensively examines the current landscape of these gene editing tools in CAR-T cell therapy, highlighting the latest advancements, persisting challenges, and future directions. Leveraging gene editing holds the potential to transform CAR-T therapy into a more potent, safer, and broadly applicable modality for cancer and beyond.
论文信息
- 作者
- Jia Z、Wu J、Zhang J、Zheng P、Zhang H、Lin Y、Pan T、Wu M
- 单位
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute. Beijing 100142, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- International journal of biological sciences2025
- 原文标识
- PubMed 41281758 · DOI 10.7150/ijbs.124144
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →